<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577472</url>
  </required_header>
  <id_info>
    <org_study_id>CANTAPOR_2012</org_study_id>
    <nct_id>NCT01577472</nct_id>
  </id_info>
  <brief_title>Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol</brief_title>
  <acronym>CANTAPOR</acronym>
  <official_title>Prospective Randomized Phase IV Study Comparing the Effect of Adding Clomiphencitrate Versus Placebo to a High Dose Versus a Minimal Dose GnRH Antagonist Protocol on the Number of Oocytes Collected From Women That Are Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the oocyte yield of infertile women with suspected or
      known poor ovarian reserve (POR) undergoing a GnRH antagonist protocol for IVF with Merional®
      starting either with a low (150 IU) or a high dose (450 IU) and adding 100mg of CC
      (Serophene®) in the early follicular phase of the stimulation (day 3 to 7). To date no RCT
      has been conducted to compare the reproductive outcome of patients with POR as defined by the
      ESHRE Bologna criteria after controlled ovarian hyperstimulation with HMG in an GnRH
      antagonist protocol using low doses versus high doses of HMG and adding CC versus placebo. We
      hypothesize that adding 100 mg of CC on day 3-7 to a HMG antagonist protocol will lead to an
      additional increment of endogenous GT thus increasing the oocytes yield after controlled
      ovarian stimulation due to higher endogenous gonadotropin secretion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">November 14, 2017</completion_date>
  <primary_completion_date type="Actual">November 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of collected oocytes</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Female Infertility</condition>
  <condition>Ovarian Insufficiency</condition>
  <arm_group>
    <arm_group_label>High Dose Clomiphencitrat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>450 IU Merional® plus 100mg Serophene®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Clomiphencitrat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 IU Merional® plus 100mg Serophene®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>450 IU Merional® plus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 IU Merional® plus Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Clomiphencitrat</intervention_name>
    <description>100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>High Dose Clomiphencitrat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Clomiphencitrat</intervention_name>
    <description>100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>Low Dose Clomiphencitrat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Placebo</intervention_name>
    <description>Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>High Dose Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Placebo</intervention_name>
    <description>Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).</description>
    <arm_group_label>Low Dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt;18 years &lt; 43 years

          -  BMI: ≥ 18 ≤ 32 kg/m2

          -  Poor responder as defined by ESHRE working group

        Exclusion Criteria:

          -  Age &lt; 18 und &gt; 43 years

          -  Pregnancy

          -  Breast feeding

          -  Uterine conditions interfering with endometrial proliferation and embryo implantation
             (submucous fibroids or polyps)

          -  Women diagnosed with PCOS according to the Rotterdam criteria

          -  Hyperprolactinaemia - untreated

          -  Both ovaries not accessible transvaginally for oocyte pick up

          -  Ovarian cysts of unclear dignity

          -  Evidence of hydrosalpinx on ultrasound

          -  Clinically significant severe systemic disease that are incompatible with pregnancy

          -  Known or suspected hypersensitivity to the active substances (gonadotrophins,
             ganirelix, progesterone, clomiphencitrate)

          -  Untreated thyroid or adrenal disorders

          -  Bleeding disorders

          -  Cancer

          -  Severe renal or hepatic dysfunction

          -  Necessity to take medication that could influence ovarian stimulation

          -  History of OHSS in prior IVF cycle
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca E Moffat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Women's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>female infertility</keyword>
  <keyword>poor ovarian response</keyword>
  <keyword>controlled ovarian hyperstimulation</keyword>
  <keyword>IVF</keyword>
  <keyword>Antagonist protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

